水蛭素及其衍生物研究进展及展望  

Progress and Prospect of Hirudin and Its Derivants Research

作　　者：于敏[1] 黄一农[1] 莫炜[1] 

机构地区：[1]复旦大学上海医学院分子医学教育部重点实验室,上海200032

出　　处：《药物生物技术》2011年第4期351-354,共4页Pharmaceutical Biotechnology

摘　　要：天然水蛭素是含有65—66个氨基酸残基的无糖基化单链多肽,分子质量约为7 000 u,由医用水蛭的唾液中分离得到,是凝血酶的特异性抑制剂,在临床治疗血栓疾病中有着重要意义。近年来多种水蛭素的衍生物被成功的开发出来,本文就重组水蛭素的研究进展进行了综述,并对其应用前景进行了展望。Natural hirudin is derived from saliva of medical leeches. It is a single-chain, carbohydrate-free polypeptide containing 65 66 amino acid with a molecular weight of 7000Da. It is a powerful and specific thrombin inhibitor, and has an important significance in clinical treatment of thrombosis diseases. Recently, several derivants of hirudin have been successfully developed, Comparing with traditional anticoagulants, they have a better therapeutic effect. We summarize the research progress of recombinant hirudin. The prospect of application is also discussed.

关 键 词：水蛭素 凝血酶 抗凝 重组水蛭素 

分 类 号：Q514.3[生物学—生物化学]